

## PROGRAM FOR THE INTERNATIONAL RESEARCH MEETING ON

## "FUTURE PERSPECTIVES IN OVARIAN CANCER RESEARCH"

## Stockholm 16-17 November 2022

Organized by the Swedish Cancer Society.

The conference is held at Karolinska University Hospital in Sune Bergström's auditorium, Solnavägen 30.

08:00-08:45	Register	
08:45	Welcome and scope of conference	Klas Kärre, Elisabeth Åvall Lundqvist, Sweden
	isk factors and prevention. Elisabeth Åvall Lundqvist, Pernilla Dahm Kähler	
09:00	Risk factors for Ovarian Cancer	Elisabete Weiderpass, Sweden
09.30	Prevention in hereditary and non-hereditary Ovarian Cancer	Ranjit Manchanda, UK
10:00	Cognitive and other side effects of prophylactic surgery	Gillian Einstein, Canada and Sweden
10:30-11:00	Break - poster exhibition	
11:00	Pro-Con discussion on risk-reducing surgery in hereditary and non-hereditary Ovarian Cancer – Pro-Con discussion	Pro: Henrik Falconer, Sweden Con: Docent Annika Strandell, Sweden
11:30	Proximal liquid biopsy for early detection of ovarian cancer	Levanon Keren, Israel
12:00	Target and genome-wide analysis approaches for early detection using liquid biopsises	Muhammed Murtaza, USA
12:30-13:30	Lunch	
	re-clinical models for translational ovarian cancel ngrid A. Hedenfalk, Kaisa Lethi	r research
13:30	Molecular and clinical heterogeneity of high-grade serous ovarian cancer	James Brenton, UK
14:00	Mouse models for BRCA1 associated tumorigenesis and genomic instability	Jos Jonkers, Netherlands
14:30	Organoid-based models for precision oncology	Krister Wennerberg, Denmark
	and research	
15:00-15:30		
	and research	Ronny Drapkin, USA
15:30	and research  Break - poster exhibition  Modeling the origins of ovarian cancer and the impact	Ronny Drapkin, USA  Michael Anglesio, Canada
15:00-15:30 15:30 16:00	and research  Break - poster exhibition  Modeling the origins of ovarian cancer and the impact of a novel tumor microenvironment component  Biomarkers and in vitro models to differentiate	
15:30 16:00	and research  Break - poster exhibition  Modeling the origins of ovarian cancer and the impact of a novel tumor microenvironment component  Biomarkers and in vitro models to differentiate subtypes of ovarian cancer histologies  Deconstruction and Reconstruction of	Michael Anglesio, Canada



	Poster award	
	New Treatment modalities Karin Sundfeldt, Ingrid A. Hedenfalk	
08:45	Ovarian cancer: therapeutic targeting of the Hallmarks of cancer in relation to subtype	Amit Oza, Canada
09:15	Opportunities and obstacles for immune therapy in ovarian cancer	Amit Oza, Canada
09:45	Genomic and immune profiling for predictivebiomarkers	Anniina Färkkilä, Finland
10:15-10:45	Break - poster exhibition	
10:45	What is optimal Ovarian Cancer Surgery - When, How and to Whom?	Pernilla Dahm -Kähler, Sweder
11:15	Fellows: Tumour and stroma responses to surgical trauma and anti-inflammatory anesthetics.	Sahar Salehi, Sweden
11:30	Unmet needs in end of life care in ovarian cancer patients	Kristina Lindemann, Norway
12:00-13:00	Lunch	
Session III I	described and an extension of	
Moderators:	New Treatment modalities continued Karin Sundfeldt, Kaisa Lethi  Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy	Emma Aneheim, Sweden
Moderators: 13:00	Karin Sundfeldt, Kaisa Lethi Fellows: Towards Curing Ovarian Carcinoma	Emma Aneheim, Sweden  Kazi Uddin, Sweden
<b>Moderators:</b> 13:00 13:15	Karin Sundfeldt, Kaisa Lethi  Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy  Fellows: Understanding the non-genetic mechanisms	
Moderators: 13:00 13:15 13:30	Karin Sundfeldt, Kaisa Lethi  Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy  Fellows: Understanding the non-genetic mechanisms of therapy resistance  Fellows: Co-targeting of HER2 and EpCAM using novel types of targeting probes for theranostics of	Kazi Uddin, Sweden
Moderators: 13:00 13:15 13:30	Karin Sundfeldt, Kaisa Lethi  Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy  Fellows: Understanding the non-genetic mechanisms of therapy resistance  Fellows: Co-targeting of HER2 and EpCAM using novel types of targeting probes for theranostics of ovarian cancer"  Fellows: "Chimeric antigen receptor T cell therapy	Kazi Uddin, Sweden Anzhelika Vorobyeva, Sweden
Moderators: 13:00 13:15 13:30 13:45 14:00-14:30	Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy Fellows: Understanding the non-genetic mechanisms of therapy resistance Fellows: Co-targeting of HER2 and EpCAM using novel types of targeting probes for theranostics of ovarian cancer" Fellows: "Chimeric antigen receptor T cell therapy for the treatment of advanced ovarian cancer"	Kazi Uddin, Sweden Anzhelika Vorobyeva, Sweden
	Karin Sundfeldt, Kaisa Lethi  Fellows: Towards Curing Ovarian Carcinoma with Targeted Alpha Therapy  Fellows: Understanding the non-genetic mechanisms of therapy resistance  Fellows: Co-targeting of HER2 and EpCAM using novel types of targeting probes for theranostics of ovarian cancer"  Fellows: "Chimeric antigen receptor T cell therapy for the treatment of advanced ovarian cancer"  Break - poster exhibition  Workshop: Strategic steps towards improved	Kazi Uddin, Sweden Anzhelika Vorobyeva, Sweden